Do analysts prefer MDP or CPH?

Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 4.23%. Given Cipher Pharmaceuticals' higher possible upside, analysts clearly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SUGR or MDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SugarBud Craft Growers 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts prefer ACB or MDP?

Aurora Cannabis currently has a consensus price target of C$7.67, indicating a potential upside of 80.39%. Given Aurora Cannabis' higher possible upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts recommend MDP or FIRE?

Given Supreme Cannabis' higher possible upside, analysts plainly believe Supreme Cannabis is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Supreme Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer EPI or MDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Medexus Pharmaceuticals (MDP) Competitors

C$4.01 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

MDP vs. CPH, SUGR, ACB, FIRE, and EPI

Should you buy Medexus Pharmaceuticals stock or one of its competitors? MarketBeat compares Medexus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medexus Pharmaceuticals include Cipher Pharmaceuticals (CPH), SugarBud Craft Growers (SUGR), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Medexus Pharmaceuticals (TSE:MDP) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Cipher Pharmaceuticals has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.43M	1.30	C$3.26M	-C$0.02	N/A
Cipher Pharmaceuticals	C$50.94M	8.13	C$11.41M	C$1.19	13.71

Medexus Pharmaceuticals has a beta of 0.526834, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.104631, suggesting that its stock price is 10% more volatile than the broader market.

Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 4.23%. Given Cipher Pharmaceuticals' higher possible upside, analysts clearly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Cipher Pharmaceuticals	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Medexus Pharmaceuticals' net margin of -0.27%. Cipher Pharmaceuticals' return on equity of 25.69% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

3.1% of Medexus Pharmaceuticals shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

SugarBud Craft Growers (CVE:SUGR) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, SugarBud Craft Growers' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
SugarBud Craft Growers	Neutral
Medexus Pharmaceuticals	Neutral

0.4% of SugarBud Craft Growers shares are owned by institutional investors. Comparatively, 3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 30.2% of SugarBud Craft Growers shares are owned by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SugarBud Craft Growers has higher revenue and earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SugarBud Craft Growers	C$662.89M	0.36	C$12.12M	C$1.40	7.15
Medexus Pharmaceuticals	C$99.43M	1.30	C$3.26M	-C$0.02	N/A

SugarBud Craft Growers has a net margin of 2.11% compared to Medexus Pharmaceuticals' net margin of -0.27%. SugarBud Craft Growers' return on equity of 10.07% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SugarBud Craft Growers	2.11%	10.07%	5.13%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

SugarBud Craft Growers has a beta of 2.768948, indicating that its stock price is 177% more volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.526834, indicating that its stock price is 47% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SugarBud Craft Growers	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

SugarBud Craft Growers beats Medexus Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Medexus Pharmaceuticals has lower revenue, but higher earnings than Aurora Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$320.59M	0.82	-C$44.16M	-C$2.14	N/A
Medexus Pharmaceuticals	C$99.43M	1.30	C$3.26M	-C$0.02	N/A

Aurora Cannabis currently has a consensus price target of C$7.67, indicating a potential upside of 80.39%. Given Aurora Cannabis' higher possible upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, Aurora Cannabis had 10 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 10 mentions for Aurora Cannabis and 0 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.28 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Medexus Pharmaceuticals	Neutral

Aurora Cannabis has a beta of 0.174133, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.526834, meaning that its stock price is 47% less volatile than the broader market.

Medexus Pharmaceuticals has a net margin of -0.27% compared to Aurora Cannabis' net margin of -12.13%. Medexus Pharmaceuticals' return on equity of -0.52% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-12.13%	-7.25%	-1.87%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

4.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 3.1% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Medexus Pharmaceuticals beats Aurora Cannabis on 11 of the 17 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Medexus Pharmaceuticals (TSE:MDP) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Supreme Cannabis has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -0.27%. Supreme Cannabis' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%
Supreme Cannabis	N/A	N/A	N/A

Given Supreme Cannabis' higher possible upside, analysts plainly believe Supreme Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Supreme Cannabis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.43M	1.30	C$3.26M	-C$0.02	N/A
Supreme Cannabis	C$53.29M	0.00	-C$23.65M	-C$0.03	N/A

In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Supreme Cannabis	Neutral

Summary

Medexus Pharmaceuticals beats Supreme Cannabis on 8 of the 12 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to ESSA Pharma?

ESSA Pharma (CVE:EPI) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ESSA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, ESSA Pharma's average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ESSA Pharma	Neutral
Medexus Pharmaceuticals	Neutral

Medexus Pharmaceuticals has higher revenue and earnings than ESSA Pharma. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ESSA Pharma	N/A	N/A	N/A	-C$0.99	N/A
Medexus Pharmaceuticals	C$99.43M	1.30	C$3.26M	-C$0.02	N/A

ESSA Pharma has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -0.27%. ESSA Pharma's return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ESSA Pharma	N/A	N/A	N/A
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

3.1% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Medexus Pharmaceuticals beats ESSA Pharma on 7 of the 10 factors compared between the two stocks.

Get Medexus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDP vs. The Competition

Export

Metric	Medexus Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$129.52M	C$2.39B	C$6.52B	C$12.19B
Dividend Yield	N/A	2.94%	2.67%	6.19%
P/E Ratio	-200.50	5.01	24.00	36.94
Price / Sales	1.30	1,642.95	514.36	10.45
Price / Cash	N/A	10.18	27.48	82.29
Price / Book	2.49	10.61	10.54	4.47
Net Income	C$3.26M	C$20.27B	C$3.57B	C$299.09M
7 Day Performance	1.52%	-0.80%	0.60%	0.65%
1 Month Performance	N/A	6.97%	1.56%	-0.08%
1 Year Performance	36.86%	16.05%	25.42%	41.90%

Medexus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDP Medexus Pharmaceuticals	N/A	C$4.01 flat	N/A	+36.9%	C$129.52M	C$99.43M	N/A	98	Gap Up
CPH Cipher Pharmaceuticals	N/A	C$16.75 +1.4%	C$17.00 +1.5%	+24.6%	C$425.30M	C$50.94M	14.08	5	Gap Up
SUGR SugarBud Craft Growers	N/A	C$12.25 +2.2%	N/A	-21.9%	C$294.85M	C$662.89M	8.75	44	Gap Up
ACB Aurora Cannabis	2.1611 of 5 stars	C$4.92 +3.4%	C$9.25 +88.0%	-46.7%	C$290.91M	C$373.12M	N/A	1,073	Earnings Report Analyst Forecast
FIRE Supreme Cannabis	N/A	N/A	N/A	N/A	C$259.40M	C$53.29M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDP) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, SUGR, ACB, FIRE, and EPI

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Summary

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, SUGR, ACB, FIRE, and EPI

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Which has higher valuation and earnings, MDP or CPH?

Which has more risk & volatility, MDP or CPH?

Do analysts prefer MDP or CPH?

Does the media favor MDP or CPH?

Is MDP or CPH more profitable?

Do institutionals and insiders hold more shares of MDP or CPH?

Summary

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

Does the media refer more to SUGR or MDP?

Do institutionals & insiders believe in SUGR or MDP?

Which has stronger valuation and earnings, SUGR or MDP?

Is SUGR or MDP more profitable?

Which has more risk & volatility, SUGR or MDP?

Do analysts rate SUGR or MDP?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Which has higher earnings and valuation, ACB or MDP?

Do analysts prefer ACB or MDP?

Does the media prefer ACB or MDP?

Which has more volatility and risk, ACB or MDP?

Is ACB or MDP more profitable?

Do insiders & institutionals believe in ACB or MDP?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Is MDP or FIRE more profitable?

Do analysts recommend MDP or FIRE?

Do institutionals and insiders believe in MDP or FIRE?

Which has stronger earnings and valuation, MDP or FIRE?

Does the media refer more to MDP or FIRE?

Summary

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Do analysts prefer EPI or MDP?

Does the media refer more to EPI or MDP?

Which has higher valuation & earnings, EPI or MDP?

Is EPI or MDP more profitable?

Do institutionals & insiders have more ownership in EPI or MDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools